Abbott Laboratories Stock News

Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.

Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 2025 and the average growth rate at 4.75%. 22 Aristocrats appear both undervalued and offer a projected long-term annualized return of at least 10%, based on dividend yield theory and earnings growth.

The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a new treatment option for patients who are not candidates for open-heart surgery or mitral repair This approval expands Abbott's portfolio of minimally invasive structural heart therapies in the U.S....

Abbott remains a Buy at $131 for its steady cash flow, strong fundamentals, and long-term healthcare growth, despite short-term revenue concerns. Wall Street underestimates ABT's operational discipline, product pipeline, and ability to manage legal and macro risks, supporting its premium valuation. Risks include legal issues, reimbursement cuts, product recalls, and FX volatility, but the compa...

Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return.

Broader equities have been volatile this year, but that's par for the course. The fact that the stock market will sometimes go through erratic periods is not a good reason not to invest.

If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.

Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.